The funds will support a multi-center clinical study investigating the test's usefulness in diagnosing elderly patients with lower respiratory tract infections.
The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.
The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.
The five-year grant will support optimizing the use of polymyxin B to treat Gram-negative bacterial infections and identify protein biomarkers of drug-associated toxicity.
In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.
The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.
A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.
The US is heading toward another budget showdown, Nature News says.